OwensDR, LandgrafW, SchmidtA, BretzelRG, KuhlmannMK. The emergence of biosimilar insulin preparations—a cause for concern?Diabetes Technol Ther, 2012; 14:989–996.
2.
ChengSW, LuJM, PanCU, WangBA, WangYZ, LiYJ, YangG, YanW. Studies of pharmacokinetic, pharmacodynamic properties and bioequivalence of recombinant insulin glargine injection in healthy man. Chin J Diabetes, 2010; 18:387–393.
HeinemannL, HompeschM. Biosimilar insulins: how similar is similar?J Diabetes Sci Technol, 2011; 5:741–754.
5.
VermaM, HazraP, IyerH, ArunA, AkundiS, DixitMN, EswaraiahA, PrasannaCG, AtignalA. Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens. Int J Diabetes Dev Ctries, 2011; 31:26–21.
6.
HeinemannL, MuchmoreD. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol, 2012; 6:728–742.
